Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Chlebowski
Rowan
R
Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502, USA. rchlebowski@gmail.com
Cuzick
Jack
J
Amakye
Dereck
D
Bauerfeind
Ingo
I
Buzdar
Aman
A
Chia
Stephen
S
Cutuli
Bruno
B
Linforth
Rick
R
Maass
Nicolaì
N
Noguchi
Shinzaburo
S
Robidoux
André
A
Verma
Sunil
S
Hadji
Peyman
P
D000328:Adult; D000368:Aged; D000077384:Anastrozole; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use; D017698:Postmenopause; D055502:Secondary Prevention; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D016387:Women's Health
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole